In a recent study published on the medRxiv * prepress server, researchers evaluated the efficacy of vaccinations against the Delta and Omicron Concern Variation (VOC) Delta and Omicron Coronavirus 2 (SARS-CoV-2) of severe acute respiratory syndrome.
Study: Advancement of the SARS-CoV-2 vaccine by Omicron and Delta variants: comparative evaluations with New York State genomic surveillance data. Image credit: JIMMOYHT / Shutterstock
Fund
Previous studies have reported that vaccinations have provided significant protection against the original strain SARS-CoV-2 (Wuhan-Hu-1); however, recently emerged SARS-CoV-2 strains have shown greater potential to cause innovative vaccine infections. Omicron has been found to contain several mutations responsible for its increased infectivity, increased immune evasion, and reduced efficacy of monoclonal antibodies and plasma antibody transfers.
About the study
The researchers evaluated the effectiveness of Delta and Omicron vaccination in the present case-control study.
For analysis, the New York State (NYS) genomic sequence data set was related to participants ’demographic and vaccination data. Adjusted age associations, vaccination type (Modern, Janssen, Pfizer), vaccination status, and time elapsed since vaccination with SARS-CoV-2 strains were assessed using odds ratios (ORs). Data were analyzed using Delta wave and Omicron logistic regression models, and the most appropriate models were decided using the Akaike information criterion (AIC) scoring system.
Respiratory swabs were obtained from study participants for real-time PCR analysis, after which SARS-CoV-2-positive swabs were subjected to whole genome sequencing (WGS) for genomic surveillance. The samples were related to demographic data from the Electronic Communicable Disease Surveillance System (CDESS) and immunization records from the NYS Immunization System (NYSIIS).
Omicron emergency analysis was performed between November 28, 2021 and January 24, 2022. Individuals with Omicron infections (all BA underlines) (cases, n = 1439) were paired with individuals infected with any other strain (controls, n = 728) during Omicron predominance period. The cases were paired with controls based on sample collection date, sex, age, and economic regions.
Delta emergency analysis was performed between March 19, 2021 and August 15, 2021, for which cases (n = 603) included individuals infected with Delta (all AY sublines) and those affected with any other SARS-CoV-2 strain except Delta. during the Delta predominance period they were considered as controls (n = 1816). Variables associated with booster vaccination were excluded from Delta emergency analysis, as booster doses were not readily available during this period.
Results
In the Omicron emergency analysis, the majority of participants (> 80%) were between 18 and 69 years old, 22% and 8% of the cases and controls, respectively, had received booster vaccinations, and the corresponding proportions of unvaccinated individuals were 30% and 56%, respectively. Among the vaccinated individuals, 177, 109, and 22 received the Pfizer, Moderna, and Janssen vaccinations, respectively. All controls in the dataset were infected by Delta.
Complete vaccinations and booster vaccinations were substantially associated with Omicron infections, with OR values of 3.1 and 6.7, respectively. The risk of Omicron infections relative to Delta infections showed a decreasing trend with advancing age (OR 0.96). The higher likelihood of Omicron infections among young individuals compared to adults could be due to more socialization and other behavioral risk factors among people 18 to 29 years of age.
By limiting the analysis to vaccinated individuals only, the likelihood of Omicron infections was reduced with increasing time since the last vaccination (OR 0.99). In addition, the likelihood of Omicron infections was lower with Janssen vaccines (OR 0.35) compared with Pfizer vaccines; (OR 0.4) in relation to any vaccination with messenger ribonucleic acid (mRNA).
In the Delta emergency analysis, most people (75%) were also between 18 and 69 years old, and 61.8% and 75% of cases and controls, respectively, were not vaccinated. Among the controls, 62%, 20%, 3.5%, and 1% of people were infected with the Alpha, Iota, Gamma, and Beta strains, respectively, and the rest were infected with other SARS- strains. CoV-2 in VOC. .
Neither the type of vaccination nor the time elapsed since the last vaccination showed a significant association with more probabilities of Delta infections compared to infection with any other SARS-CoV-2 strain. However, when the age for matching cases and controls was not considered, people who received Pfizer vaccines were 7.3 times more likely to develop Delta infections compared to any other SARS-CoV- strain infection. 2.
Conclusions
Overall, the study’s findings showed that Omicron was more elusive immune than Delta and could break the protection of the SARS-CoV-2 vaccine (including booster doses) more efficiently compared to Delta, although that Delta may be better able to overcome vaccines than previous SARS. -CoV-2 strains like Alpha.
However, the effect of time elapsed since vaccination was not assessed by stratifying individuals based on whether or not they received booster doses. The study population in the study was small to assess the effects of vaccination by vaccine type. Therefore, more research with larger sample sizes and comparison between vaccine types and between potentiated and non-potentiated individuals is required to better inform vaccine developers.
* Important news
medRxiv publishes preliminary scientific reports that are not peer-reviewed and therefore should not be considered conclusive, guided by clinical practice or health-related behavior, or treated as established information.